Waldron Private Wealth LLC boosted its stake in CVS Health Corp (NYSE:CVS) by 29.6% in the first quarter, HoldingsChannel.com reports. The fund owned 9,863 shares of the pharmacy operator’s stock after buying an additional 2,252 shares during the quarter. Waldron Private Wealth LLC’s holdings in CVS Health were worth $531,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CVS. Bay Harbor Wealth Management LLC boosted its holdings in CVS Health by 1,871.4% in the 1st quarter. Bay Harbor Wealth Management LLC now owns 552 shares of the pharmacy operator’s stock worth $30,000 after acquiring an additional 524 shares during the period. Acima Private Wealth LLC purchased a new position in CVS Health in the 4th quarter worth approximately $33,000. C J Advisory Inc purchased a new position in CVS Health in the 1st quarter worth approximately $33,000. Murphy Pohlad Asset Management LLC purchased a new position in CVS Health in the 4th quarter worth approximately $39,000. Finally, Somerset Trust Co boosted its holdings in CVS Health by 152.7% in the 1st quarter. Somerset Trust Co now owns 758 shares of the pharmacy operator’s stock worth $41,000 after acquiring an additional 458 shares during the period. Hedge funds and other institutional investors own 77.48% of the company’s stock.
Shares of CVS Health stock traded down $0.35 on Friday, hitting $54.24. 1,878,002 shares of the company’s stock traded hands, compared to its average volume of 8,695,746. The company has a current ratio of 0.95, a quick ratio of 0.64 and a debt-to-equity ratio of 1.45. The stock has a market cap of $69.71 billion, a P/E ratio of 7.66, a price-to-earnings-growth ratio of 1.08 and a beta of 0.89. CVS Health Corp has a 52-week low of $51.72 and a 52-week high of $82.15.
A number of equities analysts have weighed in on the company. Mizuho set a $71.00 price target on CVS Health and gave the stock a “buy” rating in a report on Wednesday, June 5th. CIBC reiterated a “market perform” rating on shares of CVS Health in a research note on Monday, April 15th. Raymond James reduced their target price on CVS Health from $90.00 to $75.00 and set a “strong-buy” rating for the company in a research note on Thursday, April 18th. BMO Capital Markets initiated coverage on CVS Health in a research note on Wednesday, April 10th. They set an “outperform” rating and a $58.00 target price for the company. Finally, SunTrust Banks reduced their target price on CVS Health from $85.00 to $65.00 in a research note on Wednesday, April 10th. Two analysts have rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $76.48.
CVS Health Company Profile
CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.
Further Reading: Green Investing
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.